English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

3SBio closes a $100 Million licensing Agreement with AstraZeneca

Oct. 11, 2016

On October 11, 2016, Hongkong Sansheng, a wholly-owned subsidiary of 3Sbio entered into an exclusive license agreement with AstraZeneca. Pursuant to the agreement, AstraZeneca has agreed to grant an exclusive license in China to Hongkong Sansheng for the commercialization of AstraZeneca’s Byetta, an injectable Glucagon-Like Peptide-1 receptor agonist (GLP-1 RA); and Bydureon, an extended-release formulation of exenatide, administered once weekly as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Hongkong Sansheng has agreed to pay an upfront payment of US$50,000,000 and milestone payments of up to US$50,000,000 to AstraZeneca.